Bronchial hyperresponsiveness to methacholine in patients with primary Sjögren’s syndrome

Björn Gudbjörnsson, Hans Hedenström, Gunnemar Stålenheim, Roger Häggren

Abstract
The prevalence of bronchial hyperresponsiveness (BHR) to methacholine inhalation in a consecutive series of 21 patients with primary Sjögren’s syndrome was studied prospectively. Slight to severe BHR was seen in 12/20 (60%) of the patients. Ten of 12 patients with BHR (83%) had a non-productive cough, wheezing, or intermittent breathlessness. Bronchial hyperresponsiveness was more common in patients with extra-glandular symptoms (10/14, 71%) than in those with only glandular symptoms (29%). Spirometrically 29% (6/21) of the patients had ‘small airways’ disease’, and all those had BHR. Of 6/21 (29%) who had diffuse interstitial lung disease, two had BHR. Three of the four patients with obstructive lung function were challenged with methacholine and two of them had BHR. Only two patients with BHR had normal spirometry findings. The data showed that respiratory disease—mostly mild or moderate but even severe bronchial hyperresponsiveness—is commonly seen in patients with primary Sjögren’s syndrome.

Sjögren’s syndrome is a chronic autoimmune inflammatory disease, which mainly affects exocrine glands. Sjögren’s syndrome can occur alone—primary Sjögren’s syndrome, or in association with other autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis—secondary Sjögren’s syndrome. Several visceral organs, including the lungs, may be affected in primary Sjögren’s syndrome. The respiratory manifestations include among others interstitial pneumonia, ‘small airways’ disease’, and pleuritis. Large airway obstruction has been reported in 8–12% of patients with primary Sjögren’s syndrome. In our experience severe obstructive symptoms are attributed to bronchial asthma and the diagnosis of Sjögren’s syndrome unfortunately does not become apparent until the patients develop interstitial lung fibrosis. About one third of patients with primary Sjögren’s syndrome have a chronic dry non-productive cough and dyspnoea. These symptoms are thought to be due to dryness in the large airways, secondary to a lymphocyte infiltration of the glands of the mucous membrane in the trachea. These so-called xerotrachea symptoms may, however, also imitate the symptoms of mild or moderate bronchial hyperreactivity. This clinical background induced us to investigate the prevalence of bronchial hyperresponsiveness (BHR) to methacholine inhalation in a consecutive series of patients with primary Sjögren’s syndrome. We found that most patients were hyperreactive in the test, and we correlated the methacholine test findings with clinical features and spirometric findings.

Patients and methods
A consecutive, non-selected series of patients (20 women, one man; aged 22–78 years; mean age 53.6) who were admitted to the section of rheumatology were studied. The diagnosis of primary Sjögren’s syndrome was based on the following findings: each patient had keratoconjunctivitis sicca shown by a pathological Schirmer’s test (<10 mm/5 min) and positive rose bengal staining, and xerostomia with a total salivary secretion rate stimulated by chewing of <0.7 ml/min, in the absence of other rheumatic diseases. The diagnosis was confirmed by a positive lower lip biopsy. Glandular and extra-glandular symptoms of the patients were clinically evaluated. All patients underwent serological examinations with the following tests: Waaler-Rose rheumatoid factor and antinuclear antibodies were measured at the department of clinical bacteriology, University Hospital, Uppsala. Anti-Ro (SS-A) and anti-La (SS-B) were measured by the Western blot technique at the State Bacteriological Laboratory in Stockholm, Sweden.

All subjects underwent plain chest radiography and spirometry. The spirometric test included measurements of the total lung capacity (TLC), residual volume (RV), airways resistance (Raw), and airway conductance (Gaw/V) with a body plethysmograph. Vital capacity (VC), forced vital capacity (FVC), forced expiratory volume in one second (FEV), FEVI as a percentage of VC (FEV1/VC) and of TLC (FEV1/TLC), flow volume registrations with maximal exploratory flow (Ve-max) and flows measured at 50% (Ve50) and 25% (Ve25) of FVC were measured with an Ohio spirometer. The slope of the alveolar plateau (phase III), closing volume (CV) as a percentage of VC (CV/VC), and closing capacity (CC) as percentage of TLC (CC/TLC) were determined with the single breath nitrogen washout test and the transfer factor of the lung for CO (Tlcco) was measured with the transfer test. The values obtained were compared with those for healthy controls matched for age and sex, and abnormal values were defined as values outside the 95% confidence intervals.

The methacholine test was modified from Hargreave’s method. A hand-held DeVilbiss

Rheumatology Section,
Department of Internal Medicine,
Uppsala University Hospital, S-751 85 Uppsala, Sweden
B Gudbjörnsson
R Häggren
Department of Clinical Physiology,
Uppsala University Hospital,
Uppsala, Sweden
H Hedenström
Department of Lung Medicine,
Uppsala University Hospital,
Uppsala, Sweden
G Stålenheim
Correspondence to:
Dr Gudbjörnsson.
Accepted for publication
1 February 1990


group.bmj.com on April 13, 2017 - Published by http://ard.bmj.com/
Downloaded from http://ard.bmj.com/ on April 13, 2017 - Published by group.bmj.com
Table 1  Sex, age, serology, extraglandular manifestations and respiratory symptoms in 21 patients with primary Sjögren’s syndrome

<table>
<thead>
<tr>
<th>Case No</th>
<th>Sex</th>
<th>Age (years)</th>
<th>Serology</th>
<th>Extraglandular symptoms</th>
<th>Pulmonary symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>F</td>
<td>22</td>
<td></td>
<td>Sun sensitivity</td>
<td>None</td>
</tr>
<tr>
<td>2†</td>
<td>F</td>
<td>60</td>
<td>1/125</td>
<td>Raynaud’s</td>
<td>Dry coughing</td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>38</td>
<td>1/25</td>
<td>Raynaud’s</td>
<td>Dry coughing</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>78</td>
<td>1/640</td>
<td>Raynaud’s</td>
<td>Exertional dyspnea</td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>60</td>
<td></td>
<td>BC, NEAr, HTh</td>
<td>Dry coughing</td>
</tr>
<tr>
<td>6</td>
<td>F</td>
<td>71</td>
<td>1/1600</td>
<td>NEAr, Raynaud’s, kidney stone</td>
<td>'Asthma'</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>63</td>
<td>1/1600</td>
<td>NEAr, Wmgl, polyneuropathy, kidney stone</td>
<td>Dry coughing</td>
</tr>
<tr>
<td>8</td>
<td>F</td>
<td>62</td>
<td>1/80</td>
<td>None</td>
<td>Exertional dyspnea</td>
</tr>
<tr>
<td>9†</td>
<td>F</td>
<td>55</td>
<td></td>
<td>None</td>
<td>Dry coughing</td>
</tr>
<tr>
<td>10</td>
<td>F</td>
<td>55</td>
<td></td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>11</td>
<td>F</td>
<td>40</td>
<td></td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>12††</td>
<td>F</td>
<td>41</td>
<td>1/80</td>
<td>None</td>
<td>'Asthma'</td>
</tr>
<tr>
<td>13</td>
<td>F</td>
<td>63</td>
<td></td>
<td>None</td>
<td>Exertional dyspnea</td>
</tr>
<tr>
<td>14</td>
<td>F</td>
<td>43</td>
<td></td>
<td>Kidney stone, cutaneous vasculitis</td>
<td>None</td>
</tr>
<tr>
<td>15</td>
<td>F</td>
<td>51</td>
<td>1/25</td>
<td>Sun sensitivity, Raynaud’s</td>
<td>Dry coughing</td>
</tr>
<tr>
<td>16</td>
<td>F</td>
<td>56</td>
<td>1/25</td>
<td>HTh, NEAr, Raynaud’s</td>
<td>None</td>
</tr>
<tr>
<td>17†</td>
<td>F</td>
<td>46</td>
<td>1/100</td>
<td>Raynaud’s</td>
<td>Dry coughing</td>
</tr>
<tr>
<td>18</td>
<td>F</td>
<td>38</td>
<td>1/3200</td>
<td>Kidney stone, non-Hodgkin's lymphoma, leucopenia, neuroopathy</td>
<td>Dry coughing</td>
</tr>
<tr>
<td>19</td>
<td>M</td>
<td>63</td>
<td></td>
<td></td>
<td>None</td>
</tr>
<tr>
<td>20</td>
<td>F</td>
<td>60</td>
<td></td>
<td>NEAr, Raynaud’s</td>
<td>Exertional dyspnea</td>
</tr>
<tr>
<td>21</td>
<td>F</td>
<td>50</td>
<td>1/1600</td>
<td>Raynaud’s</td>
<td>None</td>
</tr>
</tbody>
</table>

*RF=rheumatoid factor; ANA=antinuclear antibody; BC=biiliary cirrhosis; NEAr=non-erosive arthritis; HTh=hypothyroidism; Wmgl=Waldenström's macroglobulinaemia.
†Smokers; ††ex-smoker.
§—indicates a titre <1/25.

646 nebuliser was used. After an initial test with saline the patients were tested with double dilutions of methacholine, at three minute intervals, starting with 1-2 mg/ml up to a maximum dose of 20 mg/ml. The subject inhaled for two minutes actuating the nebuliser during each inhalation. The nebuliser was weighed before and after each inhalation and the consumed dose calculated. The inhalation was discontinued when there was a fall in the FEV₁ of 20% or more below the lowest post-saline value. The test result was expressed as the provocation dose which caused a fall in FEV₁ of 20% (PD20). The degree of BHR was divided into categories based on the PD20 value: severe (<0-125 mg methacholine), moderate (0-125-1-2), mild (1-3-5-0), and slight (5-1-9-0). Twenty one healthy subjects (19 women, two men; aged 29-63 years; mean age 48 years) served as controls. One was a smoker and three were ex-smokers.

**Methacholine Challenge Test Results**

Twenty patients underwent the methacholine inhalation challenge test. One patient (case No 12) had an FEV₁ lower than 1.0 l/min before methacholine inhalation and was therefore not challenged with methacholine. The bronchial response to methacholine inhalation showed that 12/20 (60%) of the patients fulfilled the criteria for BHR. One patient had severe BHR, five moderate, four mild, and two patients had slight BHR (table 2). In the reference group only two subjects had mild BHR (their PD₂₀ values were 3.2 mg and 3.4 mg).

**Clinical Symptoms and Bronchial Hyperresponsiveness**

Dry non-productive coughing and foreign body sensation in the pharynx were noted in nine of the 21 patients. No one had productive cough. Exertional dyspnoea was seen in six of the 21 patients; in two of these patients asthma had been diagnosed. They suffered from intermittent wheezing, chest tightness, and breathlessness. Two patients had a history of pleuritis and five patients had frequent respiratory infections. Only four patients had smoked (table 1). Clinical examination showed that two patients had bilateral basal rales and four patients had prolonged expiration, one of whom had forced expiratory, low pitched rhonchi.

Seven patients had no extraglandular symptoms; two of these (29%) had evidence of slight to mild BHR. One patient (case No 12)
without extraglandular symptoms was not tested because of a low postsaline FEV₁ value (FEV₁ < 1 l/min). Fourteen patients had extraglandular symptoms and 10 (71%) of these had BHR (table 3).

Ten of the 12 patients with BHR had subjective symptoms: dry non-productive cough, wheezing, or intermittent breathlessness. Two patients who had no subjective respiratory symptoms had mild and moderate BHR. Two patients had mild respiratory symptoms; one a non-productive cough and the other a mild exertional dyspnoea. Both displayed normal spirometry and methacholine inhalation tests. Two other patients with mild xerotacheitis and exertional dyspnoea respectively, had spirometrically interstitial lung disease without BHR (tables 1 and 2).

**BRONCHIAL HYPERRESPONSIVENESS AND LUNG FUNCTION**

The pulmonary functional evaluation showed that 16 of the 21 patients (76%) had abnormal spirometric findings (table 2). Based on these findings the patients were subgrouped into four groups:

**Group I:** Diffuse interstitial lung disease shown by impaired TLC and without evidence of central or peripheral obstruction. This group included six patients (29%).

**Group II:** Obstructive lung disease shown by diminished FEV₁ and sGaw (specific Gaw) with normal VC and TLC. This group included four patients (19%).

**Group III:** Small airways disease shown by diminished Ve₂₅ and with normal sGaw, FEV₁, FVC, TLC, and Tlco. This group included six patients (29%).

**Group IV:** Patients with clinical respiratory symptoms of varying intensity with normal chest radiograph and normal spirometric lung function. Two patients (10%) were in this group.

Ten of the 12 patients with BHR (83%) had pathological spirometric findings (table 4). Two of the six patients with spirometrically diffuse interstitial lung disease had evidence of BHR. Four patients had obstructive lung disease and two of three patients challenged with methacholine inhalation had slight or moderate BHR. All patients with spirometrically 'small airways disease' had BHR.

**BRONCHIAL HYPERRESPONSIVENESS AND LUNG RADIOGRAPHIC FINDINGS**

Five (24%) patients had abnormal radiological findings. Three patients had minimal diffuse interstitial densities in the lungs; two of these patients had moderate BHR. One patient had bilateral nodular intensities in the lungs. This patient was not challenged with methacholine because of a low postsaline FEV₁ (case No 12). One patient had isolated bullae in the right lung and no BHR. No patient had pleural thickenings or effusion.

**Discussion**

Bronchial hyperresponsiveness is defined as an exaggerated bronchoconstrictive response in smooth muscles with airway narrowing to a small quantity of a non-allergic stimulus that does not provoke such a reaction in normal subjects. This airway narrowing may manifest itself as episodes of coughing, dyspnoea, and wheezing after exposure to stimuli such as cold air, smoke, exercise, and pharmacological agents such as histamine and methacholine. These symptoms can mimic xerotracheal symptoms in patients with primary Sjögren's syndrome.

Our study of consecutive patients with primary Sjögren's syndrome showed that 12/20
 Bronchial hyperresponsiveness in primary Sjögren’s syndrome

(60%) had BHR of varying severity and that the BHR correlated strongly with their subjective symptoms. In a control population of similar age and sex only 10% had mild BHR. All patients, except two, with a chronic dry cough and exertional dyspnoea had severe, moderate, or mild BHR when challenged with methacholine. The two patients with mild so-called xerotracheitis and exertional dyspnoea and without BHR were spirometrically abnormal with an impaired diffusion capacity. Only two patients with evidence of BHR were without any subjective respiratory symptoms.

In clinical studies the severity of BHR due to histamine or methacholine correlates strongly with the intensity of asthma or with the bronchial obstructive symptoms and remains stable over long periods in asthmatics in the absence of exacerbating factors. The BHR also correlates with the amount of treatment required to control the symptoms of the obstructive lung disease. Asthma may exist without BHR, however, and vice versa, BHR may exist in patients without bronchial asthma—for example, in those with chronic bronchitis or upper respiratory tract infections; patients with atopy or allergy without asthma may also have a mild or slight BHR. None of our patients had an active respiratory infection at the time of evaluation and none had a history of atopy or pollen allergy. Thus it is interesting that all the patients with spirometrically small airways’ disease had BHR, while one of three treated patients with spirometrically obstructive lung function had no evidence of BHR.

Several studies have shown that the respiratory system is affected in primary Sjögren’s syndrome. In secondary Sjögren’s syndrome lung disease is often dominated by the associated autoimmune disease. Therefore, we studied only patients with primary Sjögren’s syndrome, thus avoiding confusion with respiratory manifestations of concomitant autoimmune disorders. Our study showed that 19/21 (91%) of patients with primary Sjögren’s syndrome, with or without extraglandular symptoms, had respiratory system disease, in which the major abnormality was a variable BHR response to methacholine in 12/20 (60%), followed by diffuse interstitial lung disease in 6/21 (29%) and small airways’ disease in 6/21 (29%) and, finally, obstructive ventilatory function in 4/21 (19%). Previous studies have also reported that diffuse interstitial lung disease and small airways’ disease are commonly seen in patients with primary Sjögren’s syndrome.

The mechanism behind BHR in patients with primary Sjögren’s syndrome is not known but may be related to bronchial or tracheal inflammation. Bronchial hyperreactivity in other conditions has been explained as an activation of various cell types in the airways: mast cells, alveolar macrophages, eosinophils, and neutrophils. The release of inflammatory mediators may alter the function of nerves or the response of smooth muscle cells to reflex bronchial constriction. Such postulated mechanisms may be present in patients with primary Sjögren’s syndrome, who may have an inflammatory cell infiltration of the glands in the tracheal and bronchial mucosal membrane. Additionally, increased cell counts in bronchoalveolar lavage fluid are seen in 50% of patients with primary Sjögren’s syndrome.

Our observations on BHR in primary Sjögren’s syndrome seem to have some practical clinical implications. The strong correlation between BHR and symptoms of xerotracheitis sicca suggests that either BHR is secondary to dryness of the bronchial mucus or, alternatively, that symptoms due to BHR contribute to or mimic tracheitis sicca. Studies are in progress to determine whether or not pharmacological bronchodilators or inhaled corticosteroids reduce the troublesome symptoms of tracheitis sicca. Furthermore, the observation that all patients with small airways’ disease but not all of the patients with spirometrically obstructive lung function have BHR may reflect the fact that it is the small airways that are affected and hyperresponsive to external stimuli. Thus repeated methacholine testing with progressive increases in BHR may be a better indicator than spirometry of patients at risk for developing progressive small airways’ disease. Finally, the high incidence of impaired gas diffusion in primary Sjögren’s syndrome might to some extent be influenced by an obstruction of the airways. Airway obstruction may induce an uneven distribution of alveolar ventilation, which in turn may contribute to reduced TiCO values.

In conclusion, we have shown that BHR is the major respiratory disease in patients with primary Sjögren’s syndrome. The respiratory evaluation of these patients with symptoms of chronic coughing and breathlessness should therefore include not only spirometry and chest radiographs but also a methacholine or histamine challenge test. Furthermore, the presence of primary Sjögren’s syndrome should be considered in patients complaining of a chronic cough and obstructive lung symptoms and, in particular, when the lung radiograph is abnormal and pulmonary physiological findings are not fully compatible with the findings in bronchial asthma.

We thank Eva Persson and Sonja Nordström for their excellent technical assistance. This work was supported by grants from the Söder Brauns Fund, the Swedish Medical Research Council, and the Swedish National Heart and Lung Fund.


Bronchial hyperresponsiveness to methacholine in patients with primary Sjögren's syndrome.
B Gudbjörnsson, H Hedenström, G Stålenheim and R Hälgren

*Ann Rheum Dis* 1991 50: 36-40
doi: 10.1136/ard.50.1.36

Updated information and services can be found at:
[http://ard.bmj.com/content/50/1/36](http://ard.bmj.com/content/50/1/36)

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)